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tients weighing  1 100 kg had similar rates of favorable out-
comes (45 vs. 48%, p = 0.656), good outcomes (58 vs. 64%,
p = 0.270) and mortality (17 vs. 12%, p = 0.196), and SICH risk 
(1 vs. 5%, p = 0.182). After multivariable adjustment, body 
weight  1 100 kg was strongly associated with mortality (p = 
0.007) and poor outcome (p = 0.007).  Conclusion: Our data 
do not suggest a reduced likehood of favorable outcomes in 
patients weighing  1 100 kg treated with the current dose reg-
imen. The association of body weight  1 100 kg with mortality 
and poor outcome, however, demands further large-scale 
studies to replicate our findings and to explore the underly-
ing mechanisms. 
 
Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Intravenous thrombolysis (IVT) with alteplase is cur-
rently the only approved treatment for acute ischemic 
stroke. The international stroke guidelines recommend a 
weight-adapted dose (0.9 mg alteplase per kilogram body 
weight) and a maximum dose of 90 mg for safety reasons 
 [1, 2] , meaning that no further dose adjustment is permit-
ted in patients weighing  1 100 kg. However, this recom-
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 Abstract 
 Background: Intravenous thrombolysis with alteplase for 
ischemic stroke is fixed at a maximal dose of 90 mg for safe-
ty reasons. Little is known about the clinical outcomes of 
stroke patients weighing  1 100 kg, who may benefit less from 
thrombolysis due to this dose limitation.  Methods: Prospec-
tive data on 1,479 consecutive stroke patients treated with 
intravenous alteplase in six Swiss stroke units were analyzed. 
Presenting characteristics and the frequency of favorable 
outcomes, defined as a modified Rankin scale (mRS) score of 
0 or 1, a good outcome (mRS score 0–2), mortality and symp-
tomatic intracranial hemorrhage (SICH) were compared be-
tween patients weighing  1 100 kg and those weighing  ^  100 
kg.  Results: Compared to their counterparts (n = 1,384, mean 
body weight 73 kg), patients weighing  1 100 kg (n = 95, mean 
body weight 108 kg) were younger (61 vs. 67 years, p  ! 0.001), 
were more frequently males (83 vs. 60%, p  ! 0.001) and more 
frequently suffered from diabetes mellitus (30 vs. 13%, p  ! 
0.001). As compared with patients weighing  ^  100 kg, pa-
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mendation is based on few small dose escalation studies 
 [3, 4] . On the other hand, obesity has recently risen to 
epidemic levels and the World Health Organization esti-
mates that by 2015, approximately 2.3 billion adults will 
be overweight and more than 700 million will be obese 
 [5] . Keeping in mind that obesity is an independent pre-
dictor of ischemic stroke  [6, 7] , obese patients will consti-
tute an increasing group of candidates for IVT. Further-
more, several studies reported an elevated level of plas-
minogen activator inhibitor-1 and impaired fibrinolysis 
in obese patients  [8, 9] . Thus, stroke patients weighing 
 1 100 kg may benefit less from IVT, which may have major 
therapeutic implications in clinical practice. We present 
the outcomes of patients weighing  1 100 kg compared 
with those weighing  ^  100 kg after IVT for acute isch-
emic stroke.
 Methods 
 We studied prospectively collected data of consecutive pa-
tients with acute ischemic stroke who underwent IVT at six Swiss 
stroke centers up to December 31, 2008. The Appendix provides 
detailed data about the number of patients and the study period 
for each center. Baseline investigations included neurologic and 
physical examination, assessment of stroke severity by using the 
National Institutes of Health Stroke Scale (NIHSS)  [10] , routine 
blood analysis, 12-lead electrocardiography, brain computed
tomography and/or magnetic resonance imaging. The following 
variables were ascertained: age, gender, baseline NIHSS score, 
vascular risk factors according to predefined criteria  [11] , history 
of coronary heart disease, antithrombotic medication, time to 
treatment, stroke etiology according to the Trial of Org 10172
in Acute Stroke Treatment (TOAST) criteria  [12] , blood pressure 
and blood glucose values. Body weight was measured by the unit 
nurse on admission or, when not feasible, obtained verbally from 
the patient or caregiver. Thrombolysis was applied according to 
current guidelines using intravenous alteplase 0.9 mg/kg to a 
maximum of 90 mg; 10% of the total dose was given as a bolus and 
the remaining dose within the next hour  [1, 2] . All patients treat-
ed with IVT were admitted to intermediate or intensive care units 
for at least 24 h. Follow-up CT or MRI was obtained 24–48 h after 
IVT and additional scans in case of clinical deterioration. Func-
tional outcome was assessed by outpatient visits or structured 
telephone interviews using the modified Rankin Scale (mRS)  [13] .
 Outcome Measurements 
 The primary outcome measure was the incidence of a favor-
able outcome at 3 months, defined as a mRS score of 0 or 1. We 
additionally evaluated the incidence of a good outcome, defined 
as an mRS score of 0–2. Secondarily, we assessed the mortality 
rate at 3 months and the rate of symptomatic intracranial hemor-
rhage (SICH) using both the National Institutes of Neurological 
Diseases and Stroke (NINDS) and European-Australasian Acute 
Stroke Study (ECASS) II criteria  [14, 15] .
 Statistical Analysis 
 Nonnormally distributed data were expressed as median and 
interquartile range (IQR) and compared using the Mann-Whit-
ney U test. The distribution of frequencies was examined using 
the   2 test or Fisher’s exact test where appropriate (the latter if 
some expected counts in the two-by-two table were less than 5). 
The influence of body weight ( 1 100 vs.  ^  100 kg) on the outcomes 
was examined using univariate analysis. Multivariable logistic re-
gression analyses were performed to assess joint effects of body 
weight and other predictors on the outcomes. Selection of param-
eters was based on clinical criteria and was derived from the Safe 
Implementation of Thrombolysis in Stroke-MOnitoring STudy 
(SITS-MOST) registry that evaluates outcome predictors  [16] . 
Thus, the following variables were introduced into the model: 
baseline NIHSS score, age and blood glucose for all 3 outcome 
measures; additionally, gender and diastolic blood pressure for a 
favorable outcome and mortality, and antiplatelet medication and 
systolic blood pressure for SICH. Significance was fixed at p  ! 
0.05.
 Results 
 Study Population 
 Among 1,503 stroke patients treated with IVT, 1,479 
(98%) were eligible for this study; 24 patients (2%) were 
excluded because of lacking body weight data. Of the in-
cluded 1,479 patients, 95 (6.4%) had a body weight  1 100 
kg [range 101–150 kg, mean 107.5  8 9.3 kg, median 103.0 
kg (95% CI 105.6–109.4), IQR 103–110 kg] and 1,384 
(93.6%) had a body weight  ^  100 kg [range 36–100 kg, 
mean 73.1  8 11.6 kg, median 74.0 kg (95% CI 72.4–73.7), 
IQR 66–80 kg]. The maximum dose of alteplase was 90 
mg.
 As compared with their counterparts, patients weigh-
ing  1 100 kg were younger (61 vs. 67 years of age, p  ! 
0.001) and more often men (83 vs. 60%, p  ! 0.001) with a 
higher rate of diabetes mellitus (30 vs. 13%, p  ! 0.001) 
( table 1 ). Stroke severity assessed by the baseline NIHSS 
score, time to treatment, blood pressure, antithrombotic 
medication and stroke causes were comparable in the two 
cohorts ( table 1 ).
 Outcome 
 At 3 months, clinical outcome was available in 1,462 
(99%) and classification of SICH in 1,454 (98%) of the in-
cluded 1,479 patients. All patients who were lost to follow-
up and all but 1 with undefined hemorrhage classifica-
tion had body weights  ^  100 kg.
 Favorable outcomes were observed in 694 of 1,462 
(47%) patients. The rates of patients with favorable out-
comes at 3 months were comparable between the two 
groups (45.3% of patients weighing  1 100 kg and 47.6% of 
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patients weighing  ^  100 kg, p = 0.656). After multivari-
able adjustment, age (p  ! 0.001), baseline NIHSS score
(p  ! 0.001) and blood glucose (p  ! 0.001) predicted a fa-
vorable outcome, while no association with body weight 
 1 100 kg was evident (p = 0.213) ( table 2 ). Good outcomes 
were observed at similar frequencies in patients weighing 
 ^  100 kg and those weighing  1 100 kg (63.9 vs. 57.9%, p = 
0.270) ( fig.  1 ). However, multivariable adjustment re-
vealed an independent association between good out-
come and body weight  ^  100 kg (p = 0.007) ( table 2 ).
 Death within the 3-month follow-up occurred in 184 
of 1,462 (13%) patients, and tended to be more frequent in 
patients weighing  1 100 kg (16.8 vs. 12.3%, p = 0.196). 
Multivariate logistic regression analyses identified body 
Table 1.  Baseline characteristics of alteplase-treated stroke patients with body weights >100 versus ≤100 kg
Weight >100 kg
(n = 95)
Weight ≤100 kg
(n = 1,384)
p value
Male sex, n (%) 79/95 (83.2) 827/1,383 (59.8) <0.001
Median age, years 60.1 (53.0–69.4) 70.0 (58.9–78.0) <0.0011
Hypertension, n (%) 69/95 (72.6) 882/1,384 (63.7) 0.080
Current smoking, n (%) 32/95 (33.7) 369/1,383 (26.7) 0.138
Diabetes mellitus, n (%) 28/95 (29.5) 185/1,383 (13.4) <0.001
Hypercholesterolemia, n (%) 42/83 (50.6) 611/1,353 (45.2) 0.334
Antiplatelet medication at stroke onset, n (%) 36/95 (37.9) 474/1,380 (34.3) 0.482
Anticoagulation at stroke onset, n (%) 3/95 (3.2) 37/1,380 (2.7) 0.7402
Coronary heart disease, n (%) 18/95 (18.9) 250/1,382 (18.1) 0.834
Median NIHSS score 12.0 (6–16) 12.0 (7–17) 0.3301
Median OTT, min 170.0 (135.0–180.0) 157.5 (130.0–180.0) 0.5751
Median SBP, mm Hg 151.0 (140.0–174.0) 155.0 (139.5–173.0) 0.6451
Median DBP, mm Hg 86.0 (80.0–100.0) 89.0 (79.0–100.0) 0.9701
Median blood glucose, mmol/l 6.5 (5.7–8.3) 6.4 (5.6–7.4) 0.0881
Cause of stroke
Large artery disease, n (%) 27/95 (28.4) 333/1,378 (24.2)
0.789
Cardiac embolism, n (%) 32/95 (33.7) 500/1,378 (36.3)
Small artery disease, n (%) 3/95 (3.2) 64/1,378 (4.6)
Other determined etiology, n (%) 6/95 (6.3) 112/1,378 (8.1)
Undetermined etiology, n (%) 27/95 (28.4) 369/1,378 (26.8)
U nless otherwise indicated, figures in parentheses are IQRs. p values are calculated with the 2 test, unless otherwise indicated. 
OTT = Onset-to-treatment time; SBP = systolic blood pressure; DBP = diastolic blood pressure. 1 Mann-Whitney test. 2 Fisher’s exact 
test.
Table 2.  Outcomes in patients weighing >100 kg compared with those weighing ≤100 kg
Unadjusted analysis A djusted analysis1
weight >100 kg, n weight ≤100 kg, n odds ratio and 95% CI p value odds ratio a nd 95% CI p value
Favorable outcome, mRS 0–1 43/95 (45.3%) 651/1,367 (47.6%) 0.909 (0.599–1.381) 0.656 0.715 (0.422–1.213) 0.213
Good outcome, mRS 0–2 55/95 (57.9%) 874/1,367 (63.9%) 0.776 (0.509–1.183) 0.270 0.462 (0.265–0.807) 0.007
Mortality 16/95 (16.8%) 168/1,367 (12.3%) 1.445 (0.825–2.533) 0.196 2.640 (1.305–5.341) 0.007
SICH, NINDS definition 1/94 (1.1%) 73/1,360 (5.4%) 0.190 (0.026–1.379) 0.0842 0.303 (0.041–2.251) 0.243
SICH, ECASS II definition 1/94 (1.1%) 62/1,360 (4.6%) 0.225 (0.031–1.642) 0.1822 0.372 (0.049–2.790) 0.336
p v alues apply to 2 tests, unless otherwise indicated. Figures shown in parentheses are 95% CIs, unless otherwise indicated. 1 Ad-
justed for baseline NIHSS score, age, gender, blood glucose, diastolic blood pressure (favorable outcome, good outcome, mortality); 
baseline NIHSS score, age, blood glucose, antiplatelet medication and systolic blood pressure (SICH). 2 Fisher’s exact test.
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weight  1 100 kg as an independent predictor of mortality 
(p = 0.007), along with age (p  ! 0.001), baseline NIHSS 
score (p  ! 0.001), blood glucose (p  ! 0.001) and diastolic 
blood pressure (p = 0.029) ( table  2 ). Sixteen patients 
weighing  1 100 kg died during the 3-month follow-up 
(median at day 6 after stroke onset): 15 of 16 patients were 
males, median age 66 years with a median baseline
NIHSS score of 15. The following causes of death were 
identified in these 16 patients: malignant middle cerebral 
artery infarct (n = 6), cardiopulmonary arrest (n = 5), ex-
tensive basilar artery infarct (n = 1), second ischemic 
stroke (n = 1) and aspiration pneumonia (n = 1). The re-
maining 2 patients died in external rehabilitation centers 
and the exact causes of death were not identifiable.
 Seventy-four of 1,454 (5%) patients experienced SICHs 
according to NINDS criteria, 1.1% of patients weighing 
 1 100 kg and 5.4% in the counterpart group (p = 0.084) 
( table 2 ). The rate of SICHs using the ECASS II criteria 
did not significantly differ between the two groups either 
(1.1 vs. 4.6%, p = 0.182) ( table 2 ). Multivariate logistic re-
gression analyses identified baseline NIHSS score as an 
independent predictor of SICH according to NINDS cri-
teria (p = 0.045) and ECASS II criteria (p = 0.020) but not 
body weight  1 100 kg (p = 0.243 and p = 0.336, respec-
tively) ( table 2 ).
 Discussion 
 This study aimed to assess the clinical outcomes of 
patients weighing  1 100 kg receiving intravenous alteplase 
fixed at 90 mg compared with patients weighing  ^  100 
kg, treated with weight-adapted doses of alteplase. The 
rates of favorable outcomes at 3 months were similar in 
the two groups, but an inverse association was observed 
with body weight  1 100 kg and probability of a good out-
come. Several aspects have to be considered when inter-
preting these findings: one hypothesis might be that the 
worse outcome in patients weighing  1 100 kg may be re-
lated to the lower corrected dose of alteplase in this group. 
The rather low mean body weight of 107.5 kg, which ex-
ceeds the weight cutoff (100 kg) by less than 10%, may 
have hampered our ability to detect additional differenc-
es in favorable outcome. A further, rather theoretical rea-
son for the divergent outcomes (favorable vs. good out-
come) could be the assumption that patients weighing 
 1 100 kg may be more handicapped by slight deficits due 
to overweight and associated challenges as compared to 
lean patients. In line with our findings, Lou and Selim 
 [17]  analyzed data from the NINDS trial and suggested 
less benefit of IVT in stroke patients weighing  1 100 kg as 
compared with their lighter counterparts. Lower levels of 
plasma tissue plasminogen activator and/or higher plas-
ma levels of plasminogen activator inhibitor-1 have been 
reported as a potential reason for differences in outcome 
 [8, 17, 18] . On the other hand, however, one should be cau-
tious not to overestimate our results in view of our obser-
vational study design and the small size of the cohort
of patients weighing  1 100 kg. As a consequence, further 
large-scale studies should be performed to replicate our 
findings and explore the underlying mechanisms in view 
of potential therapeutic implications.
 We are aware of mainly three studies targeting at high-
er alteplase doses for ischemic stroke. In two open-label 
dose escalation studies preceding the NINDS trial, 32 of 
94 stroke patients were treated with an alteplase dose  1 0.9 
Weight ≤100 kg
0 10
23
20
0 1 2 3 4 5 6
25 13 16 7 2 17
25 16 10 11 123
20 30 40 50
Patients (%)
60 70 80 90 100
Weight >100 kg
mRS score
 Fig. 1. Proportion of patients with body weights  1 100 kg versus  ^  100 kg according to the mRS score at 3 months. 
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mg/kg (31 patients received 0.95 mg/kg, 1 patient received 
1.08 mg/kg)  [3, 4, 14] . However, the maximal dose admin-
istered in the two studies was 86.6 mg. In the ECASS I 
trial, an alteplase dose of 0.95 mg/kg was used while the 
maximum dose was limited to 100 mg  [19] . However, no 
data were reported on the number and outcome of pa-
tients receiving alteplase doses  1 90 mg. Thus, we are not 
aware of studies that proved and reported harm following 
alteplase doses exceeding the current limit of 90 mg in 
ischemic stroke. The dose of alteplase for myocardial in-
farction is limited to 100 mg  [20] . These data indicate that 
the upper dose limit of alteplase of 90 mg seems to be 
more or less arbitrary.
 Another finding of this study is the higher mortality 
in patients weighing  1 100 kg despite their significantly 
younger age as compared with their counterparts weigh-
ing  ^  100 kg and the correlation of body weight  1 100 kg 
with mortality in the multivariate logistic regression 
analysis. The vast majority of patients weighing  1 100 kg 
who died were males (94%) and death occurred early, at 
a median of 6 days after stroke onset. Leading causes of 
death were malignant ischemic infarct and cardiopulmo-
nary arrest whereas no fatal SICH was observed in these 
patients. Obesity is associated with a higher body weight, 
and several long-term studies reported higher mortality 
rates in obese patients after ischemic stroke  [21–24] . It has 
been shown that obese stroke patients are more often 
prone to deep venous thrombosis  [25] , and other medical 
complications such as pneumonia or cardiovascular isch-
emic events appear to occur more frequently in obese pa-
tients  [21–23] . These findings do not explain our results 
completely, however, because body weight  1 100 kg does 
not always imply obesity as is the case in some athletes. 
Lou and Selim  [17]  did not report on mortality in their 
study, thus no comparison with the current literature is 
available. Nonetheless, the increased mortality observed 
in patients weighing  1 100 kg warrants further large-scale 
studies to replicate our findings and explore the mecha-
nisms as especially younger male stroke patients seem to 
be overweight, and these patients probably will represent 
a growing subgroup in the future with respect to the rap-
idly growing incidence of obesity. An increase in alteplase 
doses seems to be less promising as no randomized con-
trolled IVT trial has established that administration of 
larger doses of alteplase decreases mortality after isch-
emic strokes. The incidences of SICH (using both NINDS 
and ECASS II criteria) did not significantly differ be-
tween the two body weight groups.
 This study has some limitations. The observational 
design and the lack of a control group did not enable us 
to judge the efficacy of alteplase doses in patients weigh-
ing  1 100 kg. The cohort of patients weighing  1 100 kg was 
small, thus the possibility of a type II error cannot be ex-
cluded. We could not assess the causes of death in patients 
weighing  ^  100 kg and thus are not able to explain the 
increased mortality in patients weighing  1 100 kg com-
pletely. Measurement of plasma plasminogen activator 
concentration and assessment of the body mass index of 
patients of varying weights might have been more appro-
priate. Other factors, such as liver function, age or body 
surface area, might have additionally influenced the 
pharmacokinetics of alteplase plasma concentration  [26–
28] . Body weight was in part self-reported by patients or 
caregivers. Measurement of body weight could probably 
be more accurate  [29] although self-reported body weights 
have been reported to be valid in participants of the Nurs-
es’ Health Study II  [30] . Finally, we did not evaluate imag-
ing findings, such as early infarct signs, vessel occlusion 
or early recanalization, which might have influenced the 
outcomes as well.
 In conclusion, our data do not suggest a reduced likeli-
hood of favorable outcomes in patients weighing  1 100 kg, 
treated with the current dose regimen. The association of 
body weight  1 100 kg with mortality and a poor outcome, 
however, demands further large-scale studies to replicate 
our findings and explore the underlying mechanisms.
 Disclosure Statement 
 The authors have no disclosures to report.
 Appendix 
 Participating centers (number of patients, study period) and 
contributors in alphabetical order:
 University Hospital of Basel (359, 10 years): S.T. Engelter, P.A. 
Lyrer;  University Hospital of Bern (90, 9 years): M. Arnold, H.P. 
Mattle;  University Hospital of Lausanne (298, 8 years): P. Michel, 
C. Odier;  Cantonal Hospital of Münsterlingen (100, 9 years):
F. Müller;  Cantonal Hospital of St. Gallen (219, 5 years): P. Siebel, 
B. Weder;  University Hospital of Zurich (437, 10 years): R.W. 
Baumgartner, D. Georgiadis, H. Sarikaya.
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